Skip to Content
Merck
  • hMOB3 modulates MST1 apoptotic signaling and supports tumor growth in glioblastoma multiforme.

hMOB3 modulates MST1 apoptotic signaling and supports tumor growth in glioblastoma multiforme.

Cancer research (2014-05-30)
Fengyuan Tang, Lei Zhang, Gongda Xue, Debby Hynx, Yuhua Wang, Peter D Cron, Christian Hundsrucker, Alexander Hergovich, Stephan Frank, Brian A Hemmings, Debora Schmitz-Rohmer
ABSTRACT

New therapeutic targets are needed that circumvent inherent therapeutic resistance of glioblastoma multiforme (GBM). Here, we report such a candidate target in the uncharacterized adaptor protein hMOB3, which we show is upregulated in GBM. In a search for its biochemical function, we found that hMOB3 specifically interacts with MST1 kinase in response to apoptotic stimuli and cell-cell contact. Moreover, hMOB3 negatively regulated apoptotic signaling by MST1 in GBM cells by inhibiting the MST1 cleavage-based activation process. Physical interaction between hMOB3 and MST1 was essential for this process. In vivo investigations established that hMOB3 sustains GBM cell growth at high cell density and promotes tumorigenesis. Our results suggest hMOB3 as a candidate therapeutic target for the treatment of malignant gliomas.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cyclohexylamine, ReagentPlus®, ≥99.9%
Sigma-Aldrich
Okadaic acid from Prorocentrum concavum, 92-100% (HPLC)
Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Etoposide, synthetic, 95.0-105.0%, powder
Etoposide, European Pharmacopoeia (EP) Reference Standard